TY - JOUR
T1 - Point mutations that inactivate MGAT4D-L, an inhibitor of MGAT1 and complex N-glycan synthesis
AU - Akintayo, Ayodele
AU - Mayoral, Joshua
AU - Asada, Masahiro
AU - Tang, Jian
AU - Sundaram, Subha
AU - Stanley, Pamela
N1 - Funding Information:
We thank Rosa Barrio and James Sutherland for reagents, Donald Jarvis for S2R1 Dmfdl mutant cells, and the Flow Cytometry and Analytical Imaging and Genomics Core Facilities of the Albert Einstein Cancer Center, supported in part by the National Cancer Institute Grant PO1 13330. Funding and additional information-This work was supported by National Institutes of Health NIGMS Grant RO1 GM-105399 (to P. S.) and Einstein Core Facilities funded by National Institutes of Health NCI Grant PO1 NCI-13330 (to I. David Goldman). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
Acknowledgments—We thank Rosa Barrio and James Sutherland for reagents, Donald Jarvis for S2R1 Dmfdl mutant cells, and the Flow Cytometry and Analytical Imaging and Genomics Core Facilities of the Albert Einstein Cancer Center, supported in part by the National Cancer Institute Grant PO1 13330.
Funding Information:
Funding and additional information—This work was supported by National Institutes of Health NIGMS Grant RO1 GM-105399 (to P. S.) and Einstein Core Facilities funded by National Institutes of Health NCI Grant PO1 NCI-13330 (to I. David Goldman). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2020 American Society for Biochemistry and Molecular Biology Inc.. All rights reserved.
PY - 2020/10/9
Y1 - 2020/10/9
N2 - The membrane-bound, long form of MGAT4D, termed MGAT4D-L, inhibits MGAT1 activity in transfected cells and reduces the generation of complex N-glycans. MGAT1 is the GlcNAc-transferase that initiates complex and hybrid N-glycan synthesis. We show here that Drosophila MGAT1 was also inhibited by MGAT4D-L in S2 cells. In mammalian cells, expression of MGAT4D-L causes the substrate of MGAT1 (Man5GlcNAc2Asn) to accumulate on glycoproteins, a change that is detected by the lectin Galanthus nivalis agglutinin (GNA). Using GNA binding as an assay for the inhibition of MGAT1 in MGAT4D-L transfectants, we performed site-directed mutagenesis to determine requirements for MGAT1 inhibition. Deletion of 25 amino acids (aa) from the C terminus inactivated MGAT4D-L, but deletion of 20 aa did not. Conversion of the five key amino acids (PSLFQ) to Ala, or deletion of PSLFQ in the context of full-length MGAT4D-L, also inactivated MGAT1 inhibitory activity. Nevertheless, mutant, inactive MGAT4D-L interacted with MGAT1 in co-immunoprecipitation experiments. The PSLFQ sequence also occurs in MGAT4A and MGAT4B GlcNAc-transferases. However, neither inhibited MGAT1 in transfected CHO cells. MGAT4D-L inhibitory activity could be partially transferred by attaching PSLFQ or the 25-aa C terminus of MGAT4D-L to the C terminus of MGAT1. Mutation of each amino acid in PSLFQ to Ala identified both Leu and Phe as independently essential for MGAT4D-L activity. Thus, replacement of either Leu-395 or Phe-396 with Ala led to inactivation of MGAT4D-L inhibitory activity. These findings provide new insights into the mechanism of inhibition of MGAT1 by MGAT4D-L, and for the development of small molecule inhibitors of MGAT1.
AB - The membrane-bound, long form of MGAT4D, termed MGAT4D-L, inhibits MGAT1 activity in transfected cells and reduces the generation of complex N-glycans. MGAT1 is the GlcNAc-transferase that initiates complex and hybrid N-glycan synthesis. We show here that Drosophila MGAT1 was also inhibited by MGAT4D-L in S2 cells. In mammalian cells, expression of MGAT4D-L causes the substrate of MGAT1 (Man5GlcNAc2Asn) to accumulate on glycoproteins, a change that is detected by the lectin Galanthus nivalis agglutinin (GNA). Using GNA binding as an assay for the inhibition of MGAT1 in MGAT4D-L transfectants, we performed site-directed mutagenesis to determine requirements for MGAT1 inhibition. Deletion of 25 amino acids (aa) from the C terminus inactivated MGAT4D-L, but deletion of 20 aa did not. Conversion of the five key amino acids (PSLFQ) to Ala, or deletion of PSLFQ in the context of full-length MGAT4D-L, also inactivated MGAT1 inhibitory activity. Nevertheless, mutant, inactive MGAT4D-L interacted with MGAT1 in co-immunoprecipitation experiments. The PSLFQ sequence also occurs in MGAT4A and MGAT4B GlcNAc-transferases. However, neither inhibited MGAT1 in transfected CHO cells. MGAT4D-L inhibitory activity could be partially transferred by attaching PSLFQ or the 25-aa C terminus of MGAT4D-L to the C terminus of MGAT1. Mutation of each amino acid in PSLFQ to Ala identified both Leu and Phe as independently essential for MGAT4D-L activity. Thus, replacement of either Leu-395 or Phe-396 with Ala led to inactivation of MGAT4D-L inhibitory activity. These findings provide new insights into the mechanism of inhibition of MGAT1 by MGAT4D-L, and for the development of small molecule inhibitors of MGAT1.
UR - http://www.scopus.com/inward/record.url?scp=85092803157&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092803157&partnerID=8YFLogxK
U2 - 10.1074/jbc.RA120.014784
DO - 10.1074/jbc.RA120.014784
M3 - Article
C2 - 32763972
AN - SCOPUS:85092803157
SN - 0021-9258
VL - 295
SP - 14053
EP - 14064
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 41
ER -